United Therapeutics Corporation (UTHR) Revenue by Segment
United Therapeutics revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), United Therapeutics's largest product or service was Tyvaso, with $452.60 million or 58% of revenue, down 3.6% from a year earlier. Next: Remodulin (16%), Orenitram (16%) and Unituxin (8%).
By region, United States brought in 94% and Non-US brought in 6% of revenue in Q2 fiscal 2026.
The fastest-growing product or service from a year earlier was Unituxin (+11.6%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.
United Therapeutics Corporation
Revenue breakdown
Fiscal quarters, from company filings
United Therapeutics revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Tyvaso | $452.6M | $457.5M | $478.0M | $469.6M | 58% |
| Remodulin | $126.3M | $126.6M | $125.9M | $134.7M | 16% |
| Orenitram | $125.7M | $135.6M | $131.1M | $123.9M | 16% |
| Unituxin | $65.2M | $53.6M | $47.9M | $58.4M | 8% |
| Other | $6.8M | $5.3M | $6.9M | $5.5M | 1% |
| Adcirca | $6.7M | $2.9M | $9.7M | $6.5M | 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
United Therapeutics revenue by region, last 4 quarters
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $733.6M | $744.2M | $774.8M | $759.8M | 94% |
| Non-US | $49.7M | $37.3M | $24.7M | $38.8M | 6% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for United Therapeutics?
Tyvaso: $452.60 million, or 58% of revenue, in Q2 fiscal 2026.
What are United Therapeutics's main products and services?
By revenue in Q2 fiscal 2026: Tyvaso (58%), Remodulin (16%), Orenitram (16%) and Unituxin (8%).
Where does United Therapeutics make its money?
By region in Q2 fiscal 2026: United States (94%) and Non-US (6%).
